A cross-cultural study: anti-inflammatory activity of Australian and Chinese plants

Date

2003

Authors

Li, Rachel
Myers, S P
Leach, D N
Lin, G D
Leach, G J

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier

Abstract

In this study, in vitro inhibitory effects of 33 ethanol extracts obtained from 24 plant species (representing 11 different families) on cyclooxygenase-1 (COX-1) were evaluated. The plant materials selected for this study have been used in aboriginal medicine in Australia and traditional medicine in China for the treatment of various diseases that are considered as inflammation in nature, e.g. asthma, arthritis, rheumatism, fever, edema, infections, snakebite and related inflammatory diseases. All of the selected plants, with one exception, showed inhibitory activity against COX-1, which supports their traditional uses. The most potent COX-1 inhibition were observed from the extracts of Acacia ancistrocarpa leaves (IC50=23μg/ml). Ficus racemosa bark, Clematis pickeringii stem, Acacia adsurgens leaves, Tinospora smilacina stem and Morinda citrifolia fruit powder exhibited inhibition of COX-1 with the IC50 of 100, 141, 144, 158 and 163μg/ml, respectively. Aspirin and indomethacin used as the reference COX-1 inhibitors in this study inhibited COX-1 with IC50 of 241 and 1.2μg/ml, respectively. The findings of this study may explain at least in part why these plants have been traditionally used for the treatment of inflammatory conditions in Australian aboriginal medicine and traditional Chinese medicine.

Description

Keywords

Keywords: abrus extract; Abrus precatorius extract; acacia adsurgens extract; acacia ancistrocarpa extract; acacia catechu extract; acetylsalicylic acid; achyrathes aspera extract; alcohol; Clematis chinensis extract; clematis glycinoides extract; cyclooxygenase 1 Anti-inflammatory activity; Australian aboriginal medicine; Cyclooxygenase-1; Medicinal plants; Traditional Chinese medicine

Citation

Source

Journal of Ethnopharmacology

Type

Journal article

Book Title

Entity type

Access Statement

License Rights

Restricted until

2037-12-31